Benign outcomes of metformin for various diseases: A review

SANTHOSH G 1, *, NITHISHWAR M 1 and FATHIMA BASHEERA M 2

1 Doctor of Pharmacy, Department of Pharmacy practice, Arulmigu kalasalingam college of Pharmacy, Virudhunagar, Tamilnadu, India – 626126.
2 Assistant Professor, Department of Pharmacy Practice, Arulmigu kalasalingam college of Pharmacy, Virudhunagar, Tamilnadu , India – 626126.
 
Review Article
World Journal of Advanced Research and Reviews, 2023, 20(01), 278–286
Article DOI: 10.30574/wjarr.2023.20.1.2036
 
Publication history: 
Received on 23 August 2023; revised on 01 October 2023; accepted on 04 October 2023
 
Abstract: 
Metformin is the most popularly prescribed first-line drug in the management of type 2 diabetes mellitus. Metformin exerts different effects such as anti- hyperglycemic effect, analgesic effect in the management of musculoskeletal pain and anti-depressant effect in depression management, cardio protective and neuroprotective effects in the cardiovascular system and central nervous system. Nrf2 is the factor responsible for enhancing the anti-oxidative effects of metformin. Metformin exerts its anti-proliferative effect through the suppression of tumor development and modifies the surroundings of the tumor.
 
Keywords: 
Metformin; Diabetes mellitus; AMPK activation; Pain management; PCOS; Depression.
 
Full text article in PDF: 
Share this